Figures computed from official regulatory filings — .
Ownershipinsiders 0% · institutions 0% · short 4.1% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for 9 METERS BIOPHARMA, INC. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders in North America. Its lead product candidate is Vurolenatide, a long-acting injectable glucagon-like-peptide-1 that is in Phase 3 clinical trial to treat short bowel syndrome. The company is developing NM-136, a humanized monoclonal antibody for the treatment of obesity and obesity-related disorders; NM-102, a small molecule peptide to prevent antigens from trafficking into systemic circulation; and NM-003, a proprietary long-acting glucagon-like peptide-2 receptor agonist for prevention of acute graft versus host disease. Its partnered product is Larazotide, an 8-amino acid peptide, which is in Phase 2 clinical trial for treatment of multi-system inflammatory syndrome. The company has licensing agreements with Amunix, MHS Care Innovation LLC, Alba Therapeutics Corporation, and EBRIS. 9 Meters Biopharma, Inc. is headquartered in Raleigh, North Carolina. On July 17, 2023, 9 Meters Biopharma, Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the Eastern District of North Carolina.
Market information source · Oct 5, 2026
Periods recorded in the consulted sources. These do not certify the legal dates of name changes.
SEC company identity · Oct 5, 2026
Open-market timeline · full history
35 buys— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details |
|---|---|---|---|---|
| Madan Jay P. | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Laumas Sandeeptrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Sitar Edward J | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Laumas Sandeeptrack record | Buy | $4.6K | conv 61Cluster | SEC |
| Laumas Sandeeptrack record | Buy | $494.9 | conv 44Cluster | SEC |
| Laumas Sandeeptrack record | Buy | $721 | conv 45Cluster | SEC |
| MAIDA ANTHONY E IIItrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Proujansky Roy | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| JOHNSON LORIN Ktrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Ramasastry Saira | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Madan Jay P. | Buy | $6.6K | conv 60ClusterFirst in 12mo | SEC |
| Proujansky Roy | Buy | $1.3K | conv 69 | SEC |
| Laumas Sandeeptrack record | Buy | $6.9K | conv 83Unusual size | SEC |
| Proujansky Roy | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Ramasastry Saira | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| JOHNSON LORIN Ktrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| MAIDA ANTHONY E IIItrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Ramasastry Saira | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Proujansky Roy | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Laumas Sandeeptrack record | Buy | $2.6K | conv 51Cluster | SEC |
| Proujansky Roy | Buy | $3.7K | conv 75ClusterFirst in 12mo | SEC |
| Laumas Sandeeptrack record | Buy | $2.6K | conv 50Cluster | SEC |
| Laumas Sandeeptrack record | Buy | $2.6K | conv 52Cluster | SEC |
| Laumas Sandeeptrack record | Buy | $2.6K | conv 58 | SEC |
| Laumas Sandeeptrack record | Buy | $5.1K | conv 81Unusual size | SEC |